BioTelemetry

BioTelemetry provided remote cardiac monitoring services, centralized medical imaging, and clinical-trial core-lab support. Its flagship product, the MCOT patch, transmitted real-time ECG data to clinical monitoring centers staffed by cardiac technicians. The company also entered remote blood-glucose monitoring through the 2016 acquisition of Telcare's platform.

The business operates as Philips Ambulatory Monitoring and Diagnostics, a unit within Philips’ Connected Care segment. Key BioTelemetry executives, including long-time CEO Joseph Capper, departed after the Philips integration closed. Operational control now resides with Philips leadership, which manages the Malvern, Pennsylvania-based monitoring operations alongside its existing hospital diagnostics portfolio.

BioTelemetry secured dedicated Category I CPT codes for mobile cardiac telemetry in 2008, a landmark achievement that established standardized Medicare reimbursement rates. This coding milestone was the direct result of the 2007 Rothman Study, which demonstrated that MCOT provided a significantly higher diagnostic yield than traditional loop event monitors. The reimbursement framework lowered adoption risk for ordering physicians and created a predictable revenue stream.

Between 2012 and 2019, BioTelemetry acquired at least eight companies: ECG Scanning & Medical Services, CardioCore Lab, Mednet Technology, Biomedical Systems' cardiac unit, Radcore Lab, VirtualScopics, LifeWatch AG, and Geneva Healthcare. The LifeWatch deal in 2017 was the largest, combining the two biggest independent remote cardiac monitoring providers in the world. The roll-up consolidated fragmented competitors under a single clinical-operations platform.

No. Royal Philips closed its acquisition of BioTelemetry in February 2021. The legal entity was absorbed, and its products now fall under the Philips Ambulatory Monitoring and Diagnostics brand. The legacy gobio.com domain redirects to a Philips-hosted site, and independent financial reporting ceased with the deal closing.

BioTelemetry was a publicly traded operating company (NASDAQ: BEAT) from 2008 to 2021. It did not manage external capital like a family office or investment firm. Its capital structure relied on equity issuance during its IPO and follow-on offerings, plus debt financing to fund acquisitions. The company's value was driven by clinical service revenue, not asset management fees.

The clinical research segment, which provided core-lab services for pharmaceutical and device trials, was a meaningful revenue contributor before the acquisition. This unit, expanded through the acquisitions of CardioCore Lab and Radcore Lab, sits alongside the patient-monitoring business within Philips. Philips leverages this infrastructure to offer end-to-end services to trial sponsors, combining device data capture with centralized analysis.